EMEA-002397-PIP01-18-M02
Key facts
Invented name |
Kesimpta
|
Active substance |
Ofatumumab
|
Therapeutic area |
Neurology
|
Decision number |
P/0121/2022
|
PIP number |
EMEA-002397-PIP01-18-M02
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Novartis Europharm Limited
|
Decision type |
PM: decision on the application for modification of an agreed PIP
|